Delivery Order SPE2DP20D0002-SPE2DP26F0985
Award Date 12/1/25
Potential Completion Date 12/9/25
Potential Value $330K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed-price delivery order valued at $330,313.86 for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. The contract, issued without set-aside designation by the Defense Logistics Agency Troop Support Medical on December 1, 2025, will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents one of over 150 similar awards issued to Teva since 2023, positioning the company as a...
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- The Department of Defense's Medical Supply Chain awarded a firm-fixed-price delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. on July 14, 2025, for the supply of Adenovirus Type 4 vaccine. The contract will be performed in Parsippany, New Jersey, with an ultimate completion date of July 29, 2025. This delivery order was awarded without set-aside designation to the large business contractor, reflecting Teva's established role as a key supplier of critical immunization...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, has been awarded a delivery order valued at $660,627.72 for the supply of Adenovirus Type 4 vaccine to support critical military immunization programs. This firm-fixed-price delivery order, issued without set-aside designation, carries an ultimate completion date of December 9, 2025, just over one week from the award date of December 1, 2025. The contract is funded through the Medical Supply Chain, a defense-focused federal...
- The U.S. Department of Defense, through the Defense Logistics Agency Troop Support Medical, awarded a delivery order valued at $330,313.86 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, awarded on July 14, 2025, with a completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's...
- Teva Pharmaceuticals USA, Inc. has been awarded a delivery order valued at $330,314 for Adenovirus Type 4 vaccine supply to support federal immunization programs. The contract, awarded on July 14, 2025, with an ultimate completion date of July 29, 2025, is structured as a firm-fixed-price delivery order with no set-aside designation. Performance will take place at Teva's facility in Parsippany, New Jersey. The funding agency is the Defense Logistics Agency's Medical Supply Chain, a...